187 related articles for article (PubMed ID: 24358154)
1. Translational science by public biotechnology companies in the IPO "class of 2000": the impact of technological maturity.
McNamee L; Ledley F
PLoS One; 2013; 8(12):e82195. PubMed ID: 24358154
[TBL] [Abstract][Full Text] [Related]
2. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016.
McNamee LM; Cleary EG; Zhang S; Salim U; Ledley FD
Clin Ther; 2021 Jan; 43(1):156-171.e15. PubMed ID: 33380363
[TBL] [Abstract][Full Text] [Related]
3. Sustainability reporting and corporate reputation of Malaysian IPO companies.
Abbas YA; Mehmood W; Lazim YY; Aman-Ullah A
Environ Sci Pollut Res Int; 2022 Nov; 29(52):78726-78738. PubMed ID: 35697988
[TBL] [Abstract][Full Text] [Related]
4. Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.
Blanco-García E
MEDICC Rev; 2020 Jan; 22(1):11-16. PubMed ID: 32327617
[TBL] [Abstract][Full Text] [Related]
5. Australia's bio-regulatory framework: leading the way for stem cell research.
Hill H
J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
[TBL] [Abstract][Full Text] [Related]
6. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
7. Beyond and between academia and business: How Austrian biotechnology researchers describe high-tech startup companies as spaces of knowledge production.
Fochler M
Soc Stud Sci; 2016 Apr; 46(2):259-81. PubMed ID: 27263239
[TBL] [Abstract][Full Text] [Related]
8. Swiss Startup Framework: A Highly Effective Network Supporting the Generation of Emerging Biotech Businesses.
Mitchell I; Steiner S; Altorfer M; Suter-Dick L
Chimia (Aarau); 2020 Oct; 74(10):765-767. PubMed ID: 33115556
[TBL] [Abstract][Full Text] [Related]
9. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.
Ledley FD; McNamee LM; Uzdil V; Morgan IW
Gene Ther; 2014 Feb; 21(2):188-94. PubMed ID: 24305420
[TBL] [Abstract][Full Text] [Related]
10. Modeling timelines for translational science in cancer; the impact of technological maturation.
McNamee LM; Ledley FD
PLoS One; 2017; 12(3):e0174538. PubMed ID: 28346525
[TBL] [Abstract][Full Text] [Related]
11. Demonstrating the value of digital health: Guidance on contextual evidence gathering for companies in different stages of maturity.
Halminen O; Chen A; Tenhunen H; Lillrank P
Health Serv Manage Res; 2021 Feb; 34(1):13-20. PubMed ID: 33291977
[TBL] [Abstract][Full Text] [Related]
12. The changing environment for technological innovation in health care.
Goodman CS; Gelijns AC
Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
[TBL] [Abstract][Full Text] [Related]
13. Market entry and exit by biotech and device companies funded by venture capital.
Burns LR; Housman MG; Robinson CA
Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998
[TBL] [Abstract][Full Text] [Related]
14. Danger in the Valley of Death: how the transition from preclinical research to clinical trials can impact valuations.
Truebel H; Thurston T
Drug Discov Today; 2020 Dec; 25(12):2089-2094. PubMed ID: 33031944
[TBL] [Abstract][Full Text] [Related]
15. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
[TBL] [Abstract][Full Text] [Related]
16. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
Yamakawa K
Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
[TBL] [Abstract][Full Text] [Related]
17. A venture capital view of challenges, opportunities, and innovation in biomedical research.
Ratcliffe LT
Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
[TBL] [Abstract][Full Text] [Related]
18. H2020 EU Research & Innovation Program Boost the Transfer of Technological Breakthroughs, Enable New Solutions for Personalised Health and Impact the Industry and Healthcare Systems.
Smit PH; Lymberis A
Stud Health Technol Inform; 2015; 211():3-17. PubMed ID: 25980846
[TBL] [Abstract][Full Text] [Related]
19. Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.
Cleary EG; McNamee LM; de Boer S; Holden J; Fitzgerald L; Ledley FD
PLoS One; 2021; 16(1):e0243813. PubMed ID: 33406113
[TBL] [Abstract][Full Text] [Related]
20. Wall Street's assessment of plastic surgery--related technology: a clinical and financial analysis.
Krieger LM; Shaw WW
Plast Reconstr Surg; 2000 Feb; 105(2):609-16. PubMed ID: 10697168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
